Novesine (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride blocks voltage‑gated sodium channels on peripheral nerves of the corneal epithelium. By preventing sodium influx, it stops nerve depolarisation, which halts the transmission of pain signals. The effect is confined to the ocular surface and reverses as the drug is metabolised, restoring normal sensation within minutes.

The exact dose of Novesine is determined by the prescribing eye‑care professional. Typically, a single drop is instilled into the conjunctival sac immediately before the intended examination or procedure. The prescriber may adjust the number of drops or repeat dosing based on the specific clinical situation and patient response.

Safety data for Oxybuprocaine Hydrochloride during pregnancy or lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainty with the patient and consider alternative options when appropriate.

To order Novesine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative ophthalmic anesthetic is proparacaine. Both agents belong to the ester‑type local anesthetic class and provide rapid corneal numbness. Oxybuprocaine generally has a slightly faster onset, while proparacaine may have a marginally longer duration. Choice depends on clinician preference, patient tolerance, and specific procedural requirements.

Novesine should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from direct light and moisture. Do not freeze the product. Once opened, use within the period specified by the manufacturer and discard any solution that appears discoloured or contaminated.

Novesine is administered as an eye drop. The patient should tilt the head back slightly, pull down the lower eyelid to form a small pocket, and place a single drop onto the conjunctival sac. The eye can be gently closed for a few seconds to allow even distribution, avoiding blinking or rubbing immediately after application.

Serious adverse events, although rare, include severe allergic reactions such as angioedema or anaphylaxis and corneal complications like ulceration or a persistent epithelial defect. If the patient experiences intense swelling, difficulty breathing, marked eye pain, or worsening visual changes, immediate medical attention is required.

Novesine should be avoided in individuals with a known hypersensitivity to oxybuprocaine, other ester‑type local anesthetics, or any component of the formulation. It is also contraindicated in patients with active corneal infections, severe epithelial defects, or uncontrolled ocular inflammation, unless a specialist determines that the benefits outweigh the risks.